866-997-4948(US-Canada Toll Free)

Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018

Published By :

Global Markets Direct

Published Date : Sep 2018

Category :

Pharmaceutical

No. of Pages : 113

Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018, provides an overview of the Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a persons immune system (the bodys natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devics Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devics Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devics Syndrome) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devics Syndrome) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devics Syndrome) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devics Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 4
Neuromyelitis Optica (Devics Syndrome) - Overview 5
Neuromyelitis Optica (Devics Syndrome) - Therapeutics Development 6
Neuromyelitis Optica (Devics Syndrome) - Therapeutics Assessment 14
Neuromyelitis Optica (Devics Syndrome) - Companies Involved in Therapeutics Development 22
Neuromyelitis Optica (Devics Syndrome) - Drug Profiles 28
Neuromyelitis Optica (Devics Syndrome) - Dormant Projects 99
Neuromyelitis Optica (Devics Syndrome) - Discontinued Products 100
Neuromyelitis Optica (Devics Syndrome) - Product Development Milestones 101
Appendix 109

List of Tables
Number of Products under Development for Neuromyelitis Optica (Devics Syndrome), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Abide Therapeutics Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Acer Therapeutics Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Biogen Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Bionure Farma SL, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Endece LLC, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by LFB SA, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Tolerion Inc, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Pipeline by Vicore Pharma AB, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Dormant Projects, H2 2018
Neuromyelitis Optica (Devics Syndrome) - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Neuromyelitis Optica (Devics Syndrome), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *
  • I agree to receive other communications from Researchmoz, and allow Researchmoz to store and process my personal data.*